Researchers have announcedthat three medications have been selected for an Alzheimer’s disease prevention trial. These drugs are Gantenerumab (Roche), Solenazumab (Eli Lilly), and the BACE inhibitor (Eli Lilly), which all target beta amyloid, the protein that forms plaques in the brain. The study is projected to start in early 2013 and will include subjects who are mutation carriers of autosomal-dominant AD, making them genetically predisposed to AD at an early age. What are your thoughts on the potential to stop the process of this progressive disease?
For more information, please read th article in Reuters.